Jubilant Ingrevia share price
NSE: JUBLINGREABSE: 543271Chemicals & PetrochemicalsSmall Cap
Jubilant Ingrevia Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2021
Last close ₹593.60down ₹38.75 (6.13%)BSE ₹593.25
Share price at the NSE close on 28 Oct 2026. Previous close ₹632.35.
28 Oct: open ₹640.30, high ₹642.00, low ₹581.35
52-week range of traded prices to 28 Oct 2026
₹537.30Low, 9 Mar 2026₹795.00High, 22 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,455 Cr549th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.85
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 21,00,44849.4% delivered
About Jubilant Ingrevia
Jubilant Ingrevia Limited is a specialty chemicals company. It also runs a contract development and manufacturing (CDMO) business, serving pharmaceutical, agrochemical and semiconductor customers. Its customers also include nutrition, consumer and industrial companies. It was incorporated in 2019, and the chemicals business it carries on has more than 45 years of history.
The company reports three segments. Specialty Chemicals covers pyridine and picolines, fine chemicals and CDMO. Nutrition and Health Solutions covers vitamins, choline and premixes for both human and animal nutrition. Chemical Intermediates covers products such as acetic anhydride and ethyl acetate.
It runs more than 50 plants in India, with manufacturing sites at Gajraula in Uttar Pradesh, Bharuch and Nira. Three R&D centres employ 150 scientists, and the company has over 2,300 employees. It serves over 1,600 customers in 63 countries, including the US, the EU, Japan, the Middle East and South East Asia, as well as India. Its registered office is at Gajraula, and its corporate office is in Noida. Its equity shares are traded on the NSE and on BSE.
In the year to March 2026, it acquired Remidex Pharma Private Limited, which has since been integrated. The company's promoters include Shyam S. Bhartia, who is the founder and chairman of Jubilant Bhartia Group. A promoter is the person or group that set up a company or controls it. He also chairs the company's board, and Hari S. Bhartia is its co-chairman.
Written from the annual report for the year to Mar 2026, filed 1 Aug 2026 and the investor presentation.
Sources for 33 statements, each with its page
- It serves pharmaceutical, nutrition, agrochemical, consumer, semiconductor and industrial customers and is a specialty chemicals and CDMO company. Investor presentation, page 8
- Customers include agrochemical, consumer, semiconductor and industrial companies. Investor presentation, page 8
- CDMO business serves pharmaceuticals, agrochemicals and semiconductor sectors. Investor presentation, page 8
- Incorporated in 2019 (CIN year). Annual report, page 3
- More than 45 years of history in chemicals. Annual report, page 21
- Specialty Chemicals is a segment. Investor presentation, page 5
- Nutrition and Health Solutions is a segment. Investor presentation, page 5
- Chemical Intermediates is a segment. Investor presentation, page 6
- Specialty Chemicals includes pyridine and picolines. Annual report, page 24
- Specialty Chemicals includes fine chemicals. Annual report, page 24
- Specialty Chemicals includes CDMO. Annual report, page 24
- Nutrition works with vitamins, choline and premixes. Annual report, page 26
- Nutrition covers human nutrition. Investor presentation, page 6
- Nutrition covers animal nutrition. Investor presentation, page 6
- Shares traded on NSE and BSE. Annual report, page 74
- Chemical Intermediates include acetic anhydride. Annual report, page 26
- Chemical Intermediates include ethyl acetate. Annual report, page 26
- 50+ plants in India. Investor presentation, page 8
- Gajraula site. Investor presentation, page 4
- Bharuch and Nira sites. Investor presentation, page 4
- Three R&D centres employ 150 scientists. Investor presentation, page 8
- Over 2,300 employees. Investor presentation, page 8
- Over 1,600 customers. Annual report, page 23
- 63 countries. Annual report, page 23
- Serves US, EU, Japan, Middle East, South East Asia and domestic market. Investor presentation, page 8
- Registered office at Gajraula, Uttar Pradesh. Annual report, page 3
- Corporate office in Noida. Annual report, page 53
- Acquired Remidex Pharma in the year to March 2026. Annual report, page 50
- Remidex integration completed. Investor presentation, page 4
- Shyam S. Bhartia is founder and chairman of Jubilant Bhartia Group. Annual report, page 14
- Shyam S. Bhartia is one of the promoters of the company. Annual report, page 15
- Shyam S. Bhartia is chairman of the company. Annual report, page 14
- Hari S. Bhartia is co-chairman. Annual report, page 28
Results
Consolidated; ₹ crore.Jubilant Ingrevia quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +15.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.7%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,394 Crup 7.23%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹111 Crup 5.30%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 8.0%
Revenue by quarter
Peak revenue ₹1,394 Cr, quarter to Sep 2026; lowest ₹1,038 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,057 | 1,051 | 1,038 | 1,121 | 1,051 | 1,179 | 1,300 | 1,394 |
| Net profit | 69 | 74 | 75 | 69 | 47 | 86 | 106 | 111 |
| Net margin | 6.6% | 7.0% | 7.2% | 6.2% | 4.5% | 7.3% | 8.1% | 8.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4,388 Crup 5.04%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹278 Crup 10.65%
- Net margin
- 6.3%
Revenue by year
Peak revenue ₹4,949 Cr, year to Mar 2022; lowest ₹684 Cr, year to Mar 2021
Net profit by year, a loss in red
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 684 | 4,949 | 4,773 | 4,136 | 4,178 | 4,388 |
| Net profit | 54 | 477 | 308 | 183 | 251 | 278 |
| Net margin | 7.9% | 9.6% | 6.4% | 4.4% | 6.0% | 6.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Speciality ChemicalsSpeciality Chemicals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹2,214 Crup 7.44%47.4%
- Chemical IntermediatesChemical Intermediates, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,668 Crup 2.86%35.7%
- Nutrition & Health SolutionsNutrition & Health Solutions, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹790 Crup 5.67%16.9%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.Jubilant Ingrevia PE ratio and valuation
Price to earnings
At or below today's level on 37% of 1,174 trading days since Feb 2022.
LowestHighest
Its median35.54Industry median23.99
Price to book
At or below today's level on 19% of 1,239 trading days over the last 5 years.
LowestHighest
Its median3.37Industry median2.34
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 60% of 1,239 trading days over the last 5 years.
LowestHighest
Its median0.76%Industry median0.52%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −15.4% | +10.7% | −24.4% | 0.9% |
| 3 years | +15.7% | −3.1% | +18.4% | 0.9% |
| 5 years | +17.0% | +38.6% | −16.4% | 1.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual fund holdings
79 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 40 of the 45 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 79 funds holding Jubilant Ingrevia
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 16
- CutCut. Funds that held fewer shares than at the end of the month before.
- 29
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 30
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 DSP Small Cap FundDSP Mutual Fund | 60,02,947 | 1.83% | ₹392.1 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 36,32,989 | 0.66% | ₹237.3 Cr |
 Kotak-Small Cap FundKotak Mahindra Mutual Fund | 36,29,417 | 1.24% | ₹237.1 Cr |
 Franklin India Small Cap FundFranklin Templeton Mutual Fund | 32,97,920 | 1.51% | ₹215.4 Cr |
 Axis Small Cap FundAxis Mutual Fund | 31,11,670 | 0.66% | ₹203.3 Cr |
| DSP Midcap FundDSP Mutual Fund | 28,87,680 | 0.97% | ₹188.6 Cr |
 Edelweiss Small Cap FundEdelweiss Mutual Fund | 14,24,301 | 1.33% | ₹93.0 Cr |
 HDFC Manufacturing fundHDFC Mutual Fund | 12,05,150 | 0.77% | ₹78.7 Cr |
 UTI Small Cap FundUTI Mutual Fund | 11,71,620 | 1.46% | ₹76.5 Cr |
| HDFC Multi Cap FundHDFC Mutual Fund | 11,00,000 | 0.37% | ₹71.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Jubilant Ingrevia insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others18 purchases, 1 sale₹18 Cr₹0.62 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹17 Cr4 pledge filings of unclear kind · 11 off-market moves
- Promoters and promoter group: no market trade · 4 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Jubilant Ingrevia competitors and peers
Specialty Chemicals, 130 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Jubilant Ingrevia in market cap.Chemical companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Anupam Rasayan IndiaANURAS | 13,109 | 75.03 | 3.93 | +51.8% | +41.5% | 5.7% | 6.2% | 0.13% |
 Sudeep PharmaSUDEEPPHRM | 12,639 | 66.92 | 13.20 | – | – | 22.5% | 20.1% | 0.13% |
 Vinati OrganicsVINATIORGA | 11,214 | 25.01 | 3.55 | +5.1% | +5.4% | 15.1% | 17.3% | 0.79% |
 Elantas Beck IndiaELANTAS | 10,071 | 53.90 | 9.12 | +18.9% | +35.3% | 18.3% | 18.8% | 0.06% |
 Alkyl Amines ChemicalsALKYLAMINE | 8,449 | 37.52 | 5.51 | +5.1% | +20.6% | 15.3% | 17.6% | 0.61% |
 Clean Science and TechnologyCLEAN | 7,846 | 33.68 | 4.95 | −0.4% | −13.3% | 15.5% | 17.1% | 0.81% |
 Galaxy SurfactantsGALAXYSURF | 7,693 | 21.74 | 2.80 | +27.1% | +16.1% | 13.9% | 16.2% | 1.01% |
 Neogen ChemicalsNEOGEN | 6,822 | 191.85 | – | +18.0% | +6.0% | 4.4% | 5.8% | 0.04% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Jubilant Ingrevia dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹5.00 a share, in 5 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹2.50 |
| 10 Feb 2026 | Interim | ₹2.50 |
| 25 Jul 2025 | Final | ₹2.50 |
| 3 Feb 2025 | Interim | ₹2.50 |
| 2 Aug 2024 | Final | ₹2.50 |
| 9 Feb 2024 | Interim | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Jubilant Ingrevia announcements
Oct 2026
27 Oct · Management
27 Oct · General Updates
27 Oct · Results
14 Oct
14 Oct · Analysts
Jubilant Ingrevia share price by year
Each calendar year to 2025.Jubilant Ingrevia share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 703.45 | −14.5% | 859.20 | 580.55 |
| 2024 | 823.05 | +61.8% | 849.95 | 426.75 |
| 2023 | 508.60 | −3.8% | 534.25 | 358.50 |
| 2022 | 528.55 | −7.9% | 635.90 | 417.25 |
| 2021 | 573.70 | – | 810.15 | 254.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 19 Mar 2021.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 608.00 | 658.40 | 603.75 | 632.35 | 637.99 | 27,07,855 | 11.7% |
| 26 Oct 2026 | 600.00 | 611.70 | 595.85 | 606.00 | 604.23 | 1,33,589 | 54.8% |
| 23 Oct 2026 | 601.00 | 612.00 | 592.65 | 601.90 | 598.28 | 2,85,554 | 57.7% |
| 22 Oct 2026 | 595.00 | 612.00 | 594.05 | 609.45 | 603.43 | 2,11,983 | 41.8% |
| 21 Oct 2026 | 623.70 | 628.75 | 595.00 | 596.95 | 603.31 | 2,32,353 | 48.8% |
| 19 Oct 2026 | 635.15 | 635.90 | 621.00 | 623.70 | 624.82 | 1,19,235 | 59.0% |
| 16 Oct 2026 | 630.00 | 640.00 | 628.40 | 630.95 | 632.48 | 99,412 | 39.7% |
| 15 Oct 2026 | 648.00 | 648.00 | 629.10 | 632.70 | 637.46 | 91,085 | 43.0% |
| 14 Oct 2026 | 627.50 | 648.00 | 626.00 | 645.25 | 640.39 | 1,74,681 | 51.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- JUBLINGREA
- BSE code
- 543271
- ISIN
- INE0BY001018
- Industry
- Chemicals & Petrochemicals
- Website
- www.jubilantingrevia.com
- CIN
- L24299UP2019PLC122657
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2019
- Registered office
- Bhartiagram, Gajraula, District Amroha, 244223, Uttar Pradesh
- Share registrar
- Alankit Assignments Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, BSE SmallCap, Nifty Total Market